SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Politics : A US National Health Care System?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Road Walker who wrote (3051)12/4/2007 12:34:43 PM
From: Lane3   of 42652
 
Not irrelevant at all.

The point made was that marketing costs and development costs are independent, which they are. "Marketing costs increasing doesn't make development cost any lower," a true statement, seems to me.

You changed the subject. Sure, if competing companies produce similar drugs, marketing costs increase as companies try to focus on their versions. I agree that that's a relatively poor use of money. Differentiated drugs wouldn't require as much marketing because they would stand alone in their niche. Then marketing would not need to be directed towards brand switching but only to let patients with a particular ailment know that there's a drug treatment out there.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News